Content Type: Policy Interactions

Letter to Louisiana Secretary of Health, “Hepatitis C in Louisiana: Recommendations on Drug Availability”

April 9, 2026

Comments on Draft Intellectual Property Consultative Framework

April 9, 2026

Research Submission to Inform Medicare Drug Price Negotiation, IPAY 2028

April 9, 2026

Research Submission to Inform Medicare Drug Price Negotiation, IPAY 2027

April 9, 2026

Comments on Initial Guidance for the Medicare Drug Price Negotiation Program, IPAY 2028

April 9, 2026

Letter on S.2140, The 2024 Patent Eligibility Restoration Act (PERA)

April 9, 2026

Comments on Draft Policy, “NIH Intramural Research Program: Promoting Equity Through Access Planning”

April 9, 2026

Testimony: Making Health Care Work for American Families: Saving Money, Saving Lives

April 9, 2026

Testimony: More Cures for More Patients: Overcoming Barriers

April 8, 2026

Testimony: Drug Approval During the COVID-19 Pandemic: Following the Evidence

April 8, 2026

Testimony: Congress Should Support Development of New Treatments for Pediatric Rare Diseases, But Not with Priority Review Vouchers

April 8, 2026

Testimony: Addressing Pharmaceutical Patent Abuses Could Lower Drug Spending and Improve Patient Outcomes

April 8, 2026